# Dexa Medica Group clinical trials: 44 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 44 trials with Dexa Medica Group as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Dexa Medica Group: 44 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/dexa-medica-group

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 44
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 44, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07937462 | The Efficacy and Safety of DLBS1442 in Patients With Primary Dysmenorrhea | Dexa Medica Group | Phase 2/3 | Recruiting | Primary Dysmenorrhea | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937462) |
| November 16, 2026 | NCT07937449 | The Efficacy and Safety of DLBS3233 in Adults With Prediabetes | Dexa Medica Group | Phase 3 | Completed | Prediabetes | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937449) |
| November 16, 2026 | NCT07937436 | Bioequivalence Study of Sitagliptin/Metformin 50 mg/1000 mg Extended Release Tablet | Dexa Medica Group | Not applicable | Completed | Healthy Volunteers | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937436) |
| February 19, 2026 | NCT07420491 | The Efficacy and Safety of Reconyl in Acute Cough Treatment | Dexa Medica Group | Phase 3 | Completed | Cough | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07420491) |
| February 10, 2025 | NCT06817811 | Bioequivalence Study of Apixaban 5 mg Film-Coated Tablet | Dexa Medica Group | Phase 1 | Completed | Health | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06817811) |
| August 16, 2024 | NCT06558071 | Supplementation of Galatonol 300 mg / Striatin 30 mg in Postpartum Lactating Mothers | Dexa Medica Group | Phase 3 | Completed | Lactation Induced | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06558071) |
| August 16, 2024 | NCT06558058 | Bioequivalence Study of Rivaroxaban 10 mg Film-coated Tablets | Dexa Medica Group | Phase 1 | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06558058) |
| August 16, 2024 | NCT06558045 | Bioequivalence Study of Rivaroxaban 20 mg Film-coated Tablets | Dexa Medica Group | Phase 1 | Completed | Healthy | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06558045) |
| August 16, 2024 | NCT06558032 | Bioequivalence Study of Tamsulosin 0.4 mg Sustained Release Film-coated Tablets | Dexa Medica Group | Phase 1 | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06558032) |
| August 16, 2024 | NCT06558006 | Safety and Efficacy Predimenol for Headache | Dexa Medica Group | Phase 2 | Completed | Headache | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06558006) |
| July 19, 2024 | NCT06510257 | Safety and Efficacy Reconyl for Cough With/Without Sore Throat | Dexa Medica Group | Phase 2 | Completed | Cough | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06510257) |
| July 11, 2024 | NCT06497439 | Efficacy and Safety of Silfamin for Common Cold | Dexa Medica Group | Phase 2 | Completed | Common Cold, Sore-throat | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06497439) |
| November 13, 2023 | NCT06127225 | Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD) | Dexa Medica Group | Phase 2 | Completed | Non-Alcoholic Fatty Liver Disease (NAFLD) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06127225) |
| November 13, 2023 | NCT06127212 | Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets | Dexa Medica Group | Not applicable | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06127212) |
| February 21, 2022 | NCT05248802 | DLBS2411 Treatment For Functional Dyspepsia | Dexa Medica Group | Phase 3 | Completed | Functional Dyspepsia | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05248802) |
| February 5, 2018 | NCT03422575 | Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets | Dexa Medica Group | Not applicable | Completed | Healthy | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03422575) |
| December 8, 2017 | NCT03367195 | Efficacy and Safety of DLBS2411 in the Management of GERD | Dexa Medica Group | Phase 3 | Terminated | Gastroesophageal Reflux Disease (GERD) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03367195) |
| November 29, 2016 | NCT02976701 | Effect of DLBS1033 After Primary PCI in Patients With STE-ACS | Dexa Medica Group | Phase 2/3 | Terminated | ST Elevation Myocardial Infarction | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02976701) |
| January 21, 2016 | NCT02660060 | Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg | Dexa Medica Group | Not applicable | Completed | Healthy | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02660060) |
| August 7, 2015 | NCT02518451 | Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg | Dexa Medica Group | Not applicable | Completed | Healthy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02518451) |
| February 13, 2015 | NCT02362984 | DLBS1033 for the Treatment of Acute Ischemic Stroke | Dexa Medica Group | Phase 3 | Terminated | Acute Ischemic Stroke | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02362984) |
| October 10, 2014 | NCT02262169 | DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers | Dexa Medica Group | Phase 3 | Terminated | Non-Bleeding Peptic Ulcers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02262169) |
| September 8, 2014 | NCT02233777 | Bioequivalence Study of Two Formulations of Pregabalin Capsules 150 mg | Dexa Medica Group | Not applicable | Completed | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02233777) |
| May 26, 2014 | NCT02146664 | DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization | Dexa Medica Group | Phase 2/3 | Withdrawn | Acute Non-ST Elevation Myocardial Infarction | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02146664) |
| May 23, 2014 | NCT02145988 | DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease | Dexa Medica Group | Phase 2/3 | Terminated | Diabetes, Peripheral Arterial Disease | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02145988) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 2/3 | 8 |
| Phase 3 | 13 |
| Phase 4 | 1 |
| Not applicable | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 34 |
| Terminated | 7 |
| Withdrawn | 2 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 3 |
| Diabetes Mellitus | 3 |
| Ischemic Stroke | 3 |
| Polycystic Ovary Syndrome | 2 |
| Cough | 2 |
| Insulin Resistance | 2 |
| Breast Neoplasms | 2 |
| Dysmenorrhea | 1 |
| Thrombophilia | 1 |
| Common Cold | 1 |
| Pharyngitis | 1 |
| Gastroesophageal Reflux | 1 |
| Neoplasms | 1 |
| Neoplasm Metastasis | 1 |
| Non-alcoholic Fatty Liver Disease | 1 |
| Non-ST Elevated Myocardial Infarction | 1 |
| Endometriosis | 1 |
| Pain | 1 |
| Peripheral Arterial Disease | 1 |
| ST Elevation Myocardial Infarction | 1 |
| Acute Coronary Syndrome | 1 |
| Headache | 1 |
| Prediabetic State | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Breweries in the United States](https://specstream.ai/data/businesses/breweries/united-states)
- [Resorts in the United States](https://specstream.ai/data/businesses/resorts/united-states)
- [Gluten free restaurants in the United States](https://specstream.ai/data/businesses/gluten-free-restaurants/united-states)
- [B2B direct mail advertising companies in the United States](https://specstream.ai/data/businesses/b2b-direct-mail-advertising-companies/united-states)
- [Physical therapy clinics in the United States](https://specstream.ai/data/businesses/physical-therapy-clinics/united-states)
- [European restaurants in the United States](https://specstream.ai/data/businesses/european-restaurants/united-states)
